<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/22/biohaven-pharmaceutical-holding-co-ltd-nysebhvn-director-sells-351253-80-in-stock.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-22T23:12:41+00:00"/>
    <meta property="og:title" content="Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Sells $351,253.80 in Stock"/>
    <meta property="og:description" content="Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 6,729 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $52.20, for a total transaction of $351,253.80. The sale was disclosed in a filing with the SEC, which is available at the SEC […]"/>
  </head>
  <body>
    <article>
      <h1>Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Sells $351,253.80 in Stock</h1>
      <address><time datetime="2019-11-22T23:12:41+00:00">22 Nov 2019, 23:12</time> by <a rel="author" href="https://www.thecerbatgem.com/author/renee" target="_blank">Renee Jackson</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/biohaven-pharmaceutical-holding-co-ltd-logo.jpg"/>
      </figure>
      <p>Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 6,729 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $52.20, for a total transaction of $351,253.80. The sale was disclosed in a filing with the SEC, which is available at <a href="https://www.sec.gov/Archives/edgar/data/1262325/000168981319000097/xslF345X03/wf-form4_157447662358923.xml">the SEC website</a>.</p>
      <p>Eric Aguiar also recently made the following trade(s):</p>
      <ul>
        <li>On Friday, November 22nd, Eric Aguiar sold 1,250 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $55.24, for a total transaction of $69,050.00.</li>
        <li>On Wednesday, September 11th, Eric Aguiar sold 10,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $45.00, for a total transaction of $450,000.00.</li>
      </ul>
      <p><a href="https://www.marketbeat.com/stocks/NYSE/BHVN/insider-trades/">NYSE:BHVN</a> traded up $2.62 during midday trading on Friday, reaching $56.50. 1,293,400 shares of the stock traded hands, compared to its average volume of 710,037. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $29.17 and a 12-month high of $67.86. The stock has a market capitalization of $2.69 billion, a PE ratio of -9.19 and a beta of 0.34. The business has a 50-day moving average of $46.50 and a two-hundred day moving average of $47.40.</p>
      <p>Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.47). Equities analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -7.57 EPS for the current year.</p>
      <p>Several equities analysts recently commented on BHVN shares. Cantor Fitzgerald upped their price target on shares of Biohaven Pharmaceutical from $87.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, October 28th. Goldman Sachs Group set a $89.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, September 4th. Canaccord Genuity set a $80.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 26th. Wedbush started coverage on shares of Biohaven Pharmaceutical in a research report on Thursday. They issued an “outperform” rating and a $75.00 price objective for the company. Finally, William Blair reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $72.09.</p>
      <p>A number of institutional investors have recently modified their holdings of BHVN. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Biohaven Pharmaceutical by 16.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,618 shares of the company’s stock worth $109,000 after acquiring an additional 362 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Biohaven Pharmaceutical by 511.1% in the third quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock worth $46,000 after acquiring an additional 920 shares during the period. Glen Harbor Capital Management LLC increased its stake in shares of Biohaven Pharmaceutical by 165.9% in the second quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after acquiring an additional 1,088 shares during the period. United Services Automobile Association increased its stake in shares of Biohaven Pharmaceutical by 21.9% in the second quarter. United Services Automobile Association now owns 6,601 shares of the company’s stock worth $289,000 after acquiring an additional 1,187 shares during the period. Finally, Trellus Management Company LLC increased its stake in shares of Biohaven Pharmaceutical by 21.5% in the third quarter. Trellus Management Company LLC now owns 7,900 shares of the company’s stock worth $330,000 after acquiring an additional 1,400 shares during the period. Institutional investors and hedge funds own 90.39% of the company’s stock.</p>
      <p>
        <b>Biohaven Pharmaceutical Company Profile</b>
      </p>
      <p>Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/guidelines-for-successful-channel-trading/">Key terms to understand channel trading</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=BHVN"/>
      </figure>
    </article>
  </body>
</html>